FOSUN HEALTH Logo

Breast Cancer Diagnosis

catalogue

Breast Cancer Diagnosis

Breast Cancer Diagnosis

Diagnosis happens in two stages: confirming what the lump is, then finding out what the cancer needs. The second stage is what makes treatment specific, and it is the one most often incomplete before a patient seeks a second opinion.

Imaging: three techniques, three different questions

Each type of breast imaging answers a question the others answer poorly, which is why the examinations are used together rather than in competition.

  • Mammography

    The primary screening and first-line diagnostic test. It detects microcalcifications long before a lump is palpable. Its limitation is density: in dense breast tissue, cancer and glandular tissue can look alike, which is why density is reported alongside the result and why ultrasound is added.

  • Ultrasound

    Separates solid from cystic lesions, characterises solid masses, and evaluates the axillary lymph nodes. It is the standard supplement to mammography in dense breasts and the preferred first test in younger women and during pregnancy or breastfeeding.

  • Contrast-enhanced MRI

    The most sensitive test. It is used for lobular cancer, for dense breasts and for finding additional disease in the same or opposite breast before surgery; in screening, for women at very high genetic risk; and to judge response to drug treatment given before an operation.

Beyond these, PET-CT and bone scanning are used for staging rather than diagnosis — they look for distant spread in patients whose stage or symptoms make it likely. They are not part of routine breast assessment and are not a substitute for imaging the breast itself.

Biopsy: how tissue is obtained

Imaging can suggest cancer but cannot confirm it. The confirmation is a tissue diagnosis, and where imaging is suspicious the biopsy is planned rather than debated.

  • Core needle biopsy · the standard

    Under ultrasound, stereotactic or MRI guidance, a hollow needle takes several small cores through a small skin nick under local anaesthetic. It provides enough architecture for the pathologist to type the cancer and is sufficient for receptor testing. It takes minutes and leaves no meaningful scar.

  • Vacuum-assisted biopsy · larger samples

    Removes a larger volume of tissue through one insertion and is used for calcifications that are hard to target, for small lesions where complete removal is acceptable, and where a core biopsy yields insufficient material.

  • Fine needle aspiration · selected uses

    Uses a fine needle to sample cells rather than architecture. Most useful for confirming that an enlarged lymph node or a cyst is what imaging suggests; insufficient on its own to type a primary breast tumour.

  • Sentinel lymph node biopsy · staging, not diagnosis

    A tracer identifies the first nodes draining the breast, which are removed and examined during surgery. If they are clear, more extensive axillary surgery is avoided — sparing the arm the risk of lymphoedema.

Do not let a biopsy be skipped because the diagnosis "looks obvious". Every element of treatment — the drugs, the order of surgery, whether radiotherapy is needed — is chosen from what the tissue shows. Treating on imaging alone removes the information the plan depends on, and it cannot be recovered later from a needle that was never placed.

What the pathology report must contain

The report is the document that determines treatment. A complete one answers all of the questions below, and a report missing any of them usually means the tissue was not tested — not that the result was normal.

  • What the tissue shows

    Histological type (ductal, lobular, or a special type), whether the tumour is in situ or invasive, the grade, and the presence of lymphovascular invasion. These describe how the cancer looks and how aggressively it is behaving at the tissue level.

  • What drives it

    Oestrogen receptor and progesterone receptor status with percentages, HER2 status with the scoring method (immunohistochemistry, with in situ hybridisation where the result is equivocal), and Ki-67 as a proliferation index. These four results place the cancer in a treatment group.

  • Molecular profiling, where relevant

    NGS panels looking for PIK3CA, ESR1, AKT, NTRK, RET and other actionable changes; germline BRCA1/BRCA2 testing for patients who qualify; and where available a gene-expression assay used to decide whether chemotherapy adds anything to endocrine treatment in early hormone receptor-positive disease.

  • Why an incomplete report is worth re-testing

    Receptor and HER2 results can be re-run on existing blocks and, in China, reported within a short interval. This is the single most common reason a second opinion changes management — not a different opinion about the operation, but a different result on a test that had not been ordered.

Tumour markers and blood tests

Blood tests do not diagnose breast cancer and are not used for screening. Their role is different: they establish a baseline and provide one of several ways of following the disease once treatment has begun.

Test What it is used for What it cannot do
CA 15-3 and CA 27.29 Following the course of known metastatic disease alongside imaging Screen for or diagnose breast cancer; a normal result never excludes disease
CEA A secondary marker, sometimes informative when CA 15-3 is not Distinguish breast cancer from other common causes of a raised result
Full blood count and biochemistry Establishing organ function before chemotherapy, and monitoring its effect Provide any information about the tumour itself
Circulating tumour DNA An emerging option in selected patients, mainly to detect actionable changes when a new biopsy is difficult Replace tissue testing where tissue can be obtained

Staging: what actually gets examined

Staging is a separate process from diagnosis, and it is planned according to what the diagnosis and examination already suggest rather than applied uniformly.

  • Early-stage disease

    For a small tumour without clinical nodal involvement, staging is usually limited to imaging of the breast, examination of the axilla, and a chest assessment. Extensive whole-body scanning is not routinely required and can create findings that are difficult to interpret.

  • Locally advanced or symptomatic disease

    Large tumours, fixed nodes, inflammatory features or symptoms suggesting spread are staged with CT of the chest, abdomen and pelvis, a bone scan or PET-CT, and imaging of the brain where there are neurological symptoms. This is where distant disease is found or excluded.

  • What staging changes

    Whether surgery comes first or drug treatment does. Stage I to II disease generally goes to surgery, with the pathology then guiding what follows. Stage III disease commonly begins with drug treatment, and stage IV disease is treated systemically with local treatment reserved for particular sites.

  • What staging does not change

    The molecular profile. A stage IV hormone receptor-positive tumour is treated with endocrine-based therapy irrespective of how many sites are involved, and a stage I triple-negative tumour is not. Stage and biology are read together; either one alone produces a worse answer.

Getting an answer from abroad, and how long it takes

A work-up can begin before any decision to travel is made, and for many patients it should. The first step is a records review, which produces a written opinion that is yours to use anywhere.

Send these so the panel can start:

  • Imaging
  • — mammogram, ultrasound and MRI in DICOM format, plus any earlier studies so that change over time can be judged rather than a single snapshot
  • Pathology
  • — the biopsy or surgical specimen report in full, including histological type, grade, tumour size and margin status
  • Receptor and molecular results
  • — oestrogen and progesterone receptor percentages, HER2 status with the test method, Ki-67, and any NGS or germline results already performed
  • Blood results
  • — full blood count, liver and kidney function, and any tumour marker values recorded
  • A short summary
  • — what has been done so far, in what order, and what the treating team has proposed and why

Pathology blocks or slides can be re-reviewed and receptor testing repeated if it was not done or was incomplete. Results are returned in writing; the timeline depends on whether new testing is needed, not on travel.

If the diagnosis is already confirmed and you are deciding what to do about it, the next page sets out the treatment options and the order in which they are usually given. If nothing has been found yet and you are trying to establish whether a change matters, start with symptoms and early warning signs.

Frequently Asked Questions

Can a biopsy make the cancer spread?

No. This is one of the most persistent fears around breast biopsy and it is not supported by the evidence. Needle biopsy has been used for decades, and studies comparing patients who had biopsy with those who went straight to surgery have not shown that it causes spread. The theoretical concern is also addressed by technique: the needle track is planned so that it can be removed with the tumour at the time of surgery.

What does it mean if the receptor tests are negative?

It means the tumour is not driven by oestrogen or progesterone, so endocrine therapy will not work against it. It does not mean there is no treatment. If HER2 is also negative the tumour is triple-negative, and treatment is based on chemotherapy, with immunotherapy added where the tumour expresses PD-L1. If the receptor tests were run on a small or poorly handled sample, repeating them on a larger specimen can change the result.

Why do I need an MRI as well as a mammogram?

Because the two tests see different things, and MRI is markedly more sensitive. It is used to map the extent of disease within the breast, to look for additional tumours that mammography and ultrasound have missed, and to assess the opposite breast in certain situations. It is also the best available way to judge whether a tumour given drug treatment before surgery is shrinking. Its sensitivity is also its drawback — MRI produces more findings that turn out to be benign, which is why it is used selectively rather than universally.

How quickly can a diagnosis be completed?

Imaging and biopsy can usually be completed within days once you are seen, and a standard pathology report takes several working days after the tissue reaches the laboratory. Receptor testing adds further time, and molecular profiling longer still. The practical answer is that the sequence is fixed and the pace is not: the value of doing it in order is that each result is interpreted in the light of the one before it, rather than arriving as a set of disconnected numbers.

Patient Stories

Stories from our breast cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Send your pathology and imaging, get a written plan

Upload your mammogram, ultrasound, MRI and biopsy report, including receptor and molecular results if available. Our breast cancer multidisciplinary team will return a written assessment within 48 hours of the file being complete — whether you are deciding on surgery, facing a treatment that has stopped working, or want a second opinion before committing to a course of treatment at home.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

WhatsApp +86 172-7459-8280 · EN / 中文 · 24h within business hours

Follow Fosun Health

Apply for an Appointment

Do you have test results*